About CellGate
CellGate is a company based in Redwood City (United States) founded in 1998 was acquired by TBG Diagnostics in February 2008. CellGate has raised $10 million across 1 funding round from investors including Johnson & Johnson, TBG Diagnostics and NEA. CellGate operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Redwood City, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Cellgate, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$10 M (USD)
in 1 rounds
-
Latest Funding Round
$10 M (USD), Series D
Sep 19, 2002
-
Investors
Johnson & Johnson
& 2 more
-
Employee Count
Not available
-
Acquired by
TBG Diagnostics
(Feb 04, 2008)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of CellGate
CellGate has successfully raised a total of $10M through 1 strategic funding round. The most recent funding activity was a Series D round of $10 million completed in September 2002. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CellGate
CellGate has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Johnson & Johnson, TBG Diagnostics and NEA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Healthcare solutions are provided by Johnson & Johnson globally.
|
Locked | Locked | Locked | |
|
Molecular diagnostics kits, instruments, and software are developed and manufactured.
|
Locked | Locked | Locked |
Investor details for CellGate
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CellGate
Investment portfolio details for CellGate
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CellGate
Detailed financials for CellGate
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cellgate Comparisons
Peer comparison for CellGate
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CellGate
CellGate operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of CellGate
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cellgate
Complete news archive for CellGate
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CellGate
CellGate was founded in 1998 and raised its 1st funding round 4 years after it was founded.
CellGate is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
CellGate is a funded company, having raised a total of $10M across 1 funding round to date.
CellGate was founded in 1998 in Redwood City, United States, and operated in the oncology sector. A portfolio of drug candidates was maintained, including one in Phase 1 trials and several preclinical compounds. The lead candidate, CGC11047, a polyamine analog, was evaluated for anti-tumor effects via inhibition of polyamine and epigenetic pathways. The company was acquired by Progen Pharmaceuticals Ltd in 2008.
CellGate's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
CellGate has 3 investors. Key investors include Johnson & Johnson, TBG Diagnostics, and NEA.